Phase I trial comparing bile acid and short-chain fatty acid alterations in stool collected from human subjects treated with omadacycline or vancomycin.

• Tác giả: M Jahangir Alam, Khurshida Begum, Kevin W Garey, Sigmund J Haidacher, Thomas D Horvath, Chenlin Hu, Jinhee Jo
• Ngôn ngữ: eng
• Ký hiệu phân loại: 627.12 Rivers and streams
• Thông tin xuất bản: United States : Antimicrobial agents and chemotherapy , 2025
• Bộ sưu tập: NCBI
• ID: 60663

Tóm tắt

UNLABELLED: Omadacycline, an aminomethylcycline tetracycline, has a low propensity to cause IMPORTANCE: The purpose of this study was to assess bile acid and SCFA changes in stool samples obtained from healthy volunteers given omadacycline or vancomycin. Stool samples were collected daily from 16 healthy volunteers given a 10-day oral course of omadacycline or vancomycin. Vancomycin caused a larger change in the primary bile acids and SCFA concentrations compared with omadacycline. The metabolic findings help further our understanding of the mechanistic basis for the lower-risk properties of omadacycline causing CDI and warrant phase 2 investigations using omadacycline as a CDI antibiotic. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT06030219.